The company received a cash prize from the NIH. HemoChrome will meet with NIH experts twice a week to move on to the next phase of the NIH challenge, according to a Feb. 15 Purdue news release.
“Conventional blood hemoglobin tests are usually conducted by invasive and expensive venous blood draws, which require sophisticated equipment, highly trained experts to run the tests and patients who must be present on-site with their health care provider,” Young Kim, PhD, HemoChrome’s founder and a professor at Purdue, said. “Our simple app is intended to eliminate these barriers and make these tests accessible to everyone, especially those in health care deserts, by allowing clinicians to conduct point-of-care, home-based and remote diagnostic tests on their patients at a fraction of the cost.”
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
